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Introduction: Inhaled nitric oxide (iNO) is an important therapy for acute respiratory distress syndrome (ARDS),
pulmonary hypertension and pediatric hypoxemic respiratory failure. Safety concerns regarding iNO and renal
dysfunction have been reported; however, there are currently no systematic reviews on this issue. Our objective
was to evaluate published randomized controlled trials (RCTs) to ascertain the risk of renal dysfunction associated
with iNO therapy in patients with and without ARDS.
Methods: A systematic review of databases was performed to identify RCTs which compared iNO with controls up
to September 2014. Effect estimates for risk ratio (RR) of acute kidney injury (AKI) were pooled using a random-effects
model.
Results: Ten RCTs involving 1363 participants were included. Inhaled nitric oxide significantly increased the risk of
AKI compared with controls (RR, 1.4, 95%CI, 1.06 to 1.83, p = 0.02). In the stratified analysis, a high cumulative-dose
of iNO significantly increased the risk of AKI (RR, 1.52, 95%CI, 1.14 to 2.02, p = 0.004), whereas medium and low
cumulative-doses did not (RR, 0.64, 95%CI, 0.23 to 1.81 and RR, 0.56, 95%CI, 0.11 to 2.86 respectively). In subgroup
analysis by study population, an increased risk of AKI was observed in patients with ARDS (RR, 1.55, 95%CI, 1.15 to
2.09, p = 0.005) but not in those without (RR, 0.90, 95%CI, 0.49 to 1.67, p = 0.75).
Conclusions: The available data show that iNO therapy may increase the risk of renal dysfunction, especially with
prolonged use and in patients with ARDS. The risk in pediatric population is unknown owing to limited data. We
suggest monitoring renal function during iNO therapy, and that future trials of iNO should evaluate renal safety.Introduction
Nitric oxide was first reported to be an endogenous
vasodilator in 1987 [1]. Soon after this discovery, inhaled
nitric oxide (iNO) was applied to treat pulmonary hyper-
tension and various pulmonary diseases [2,3]. Previous
studies and clinical trials have shown that iNO possesses
the therapeutic effects of selective pulmonary vasodilata-
tion without causing systemic hypotension, and an effect
on improving ventilation-perfusion mismatch [3,4]. Cur-
rently, iNO has been an important treatment modality
for pulmonary hypertension, acute respiratory distress* Correspondence: syruan@ntu.edu.tw; mslai@ntu.edu.tw
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unless otherwise stated.syndrome (ARDS), and pediatric hypoxemic respiratory
failure [5-7].
Cumulative data from physiological studies and clinical
trials suggest that iNO therapy has a good safety profile
[8-10], and that its potential adverse effects, including
methemoglobinemia, inhibition of platelet aggregation and
systemic vasodilatation, are usually clinically insignificant
[8,11,12]. However, a safety concern about renal dysfunc-
tion for nitric oxide inhalation was reported in a meta-
analysis designed to evaluate the efficacy of iNO in ARDS
[13]. This finding contradicts earlier evidence that iNO
has favorable effects on renal and splanchnic perfusion
[8]. In addition, this adverse effect, as a class effect of iNO
therapy, was not observed in non-ARDS populations.
These contrasting findings warrant further investigation
to clarify the association between iNO and the risk of
renal dysfunction in patients with and without ARDS.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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analysis to ascertain the risk of acute kidney injury (AKI)
in iNO therapy and to investigate whether the risk varies
among different patient populations.
Materials and methods
Search strategy
This systematic review was conducted using an a priori
published protocol submitted to the PROSPERO website
(Registration number CRD42013005731) and reported
according to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) criteria [14].
No institutional review board approval or consents were
needed for this systematic review because it evaluated
published studies. We searched MEDLINE via the NCBI
Entrez system and Cochrane Central Register of Con-
trolled Trials up to 25 September 2014. Bibliographies of
retrieved studies and recent review articles were also
screened to identify additional trials. Both keywords and
MeSH terms searches were used to identify relevant cita-
tions. The search terms were “inhaled nitric oxide” AND
“randomized controlled trial”, and MeSH terms were
“Nitric Oxide/therapeutic use” [Mesh] AND “Random-
ized Controlled Trial” [Publication Type]. There were no
language restrictions. Details of our search strategy are
shown in the online appendix (see Additional file 1).
The eligible studies were parallel randomized controlled
trials (RCTs) comparing patients who did and did not
receive iNO therapy. The exclusion criteria included
crossover trials and studies not reporting AKI in the
results.
Study selection and data extraction
Two investigators (SYR and TMH) screened studies for
inclusion and independently extracted data from the
included studies. Any disagreements were resolved by
discussion. A standardized recording form was used for
data extraction.
Assessment of risk of bias
Quality assessment of these studies was done using the
Cochrane Collaboration tool for assessing the risk of
bias [15]. We assessed the risk of bias associated with
random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of out-
come assessments, incomplete outcome data, selective
outcome reporting, and other bias. Two investigators
(SYR and TMH) independently assessed the risk of bias
in the individual studies, and discrepancies were resolved
by consensus.
Outcome measures
The primary outcome of interest was AKI as defined in
the individual studies regardless of the severity of injury.The secondary outcome was AKI requiring renal re-
placement therapy (RRT). Risk ratio (RR) was used as a
measurement of association in the analysis.
Stratified analysis
Stratified analysis by study population was performed to
investigate whether the risk of iNO-associated renal dys-
function varied among different patient populations. To
test the dose-response relationship between iNO and the
risk of renal dysfunction, stratified analysis by duration
and dosage of iNO therapy was also performed.
Data synthesis
Outcome measures were pooled using a random-effects
model with the inverse variance method because of an-
ticipated heterogeneity among the included studies. We
analyzed data by intention-to-treat analysis and calcu-
lated the point estimates and 95% CI of the summary
effect. When one arm of a study contained no events,
0.5 was added to all cells of the two-by-two table [16].
Sensitivity analysis was performed to check the robust-
ness of the effect estimate using different data synthesis
models. The Peto method was used in the sensitivity
analysis because of its advantage of a less biased estimate
for summary effect in the settings of sparse data and im-
balance of trial size [17]. Because the Peto method can
only be used to calculate odds ratios (ORs), we also cal-
culated ORs using a random-effects model to compare
the effect sizes obtained by these two methods. Hetero-
geneity was explored using the Q-statistic and I2. Het-
erogeneity was considered low, moderate, and high
according to I2 values of <25%, 25 to 50% and >50%,
respectively [18]. Publication bias was evaluated by a
funnel plot of standard error versus RR based on the
primary outcome, and with Egger’s test [19]. For all ana-
lyses, a two-sided P-value <0.05 was considered to be
statistically significant. The data were analyzed using
Stata software, version 11 (StataCorp, Texas, USA).
Results
Literature search and study characteristics
Through the electronic searches and from references,
252 citations were identified. According to our prede-
fined inclusion and exclusion criteria, 10 RCTs involving
a total of 1,363 patients were included in the final ana-
lysis [12,20-28]. To calculate the risk for incident AKI,
26 patients were excluded from the analysis because they
had received hemodialysis before the enrollment of trials.
The number of studies evaluated at each stage of the lit-
erature review is shown in Figure 1. Quality assessment
(see Additional file 2) of the included studies suggested a
low risk of bias, except for one study which was published
with an abstract [21].
Records identified through






Records after duplicates removed
(n = 252)
Full text articles assessed for eligibility
(n = 146)
Records excluded (n = 106)
Not RCT (76)
No full text (6)
Irrelevant to the topic (24)
(n = 136)
No report of kidney injury (74)
Crossover trials or not randomised
for inhaled nitric oxide (62)
Studies included in systematic review
(n = 10)
Studies included in quantitative synthesis 
Full text articles excluded, with reasons
(meta analysis)
(n = 10)
Figure 1 Study flow through this systematic review. RCT, randomized controlled trial.
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rized in Table 1. The publication year ranged from 1998
to 2014, and included four studies on patients with ARDS,
four studies on patients undergoing surgery, one study on
neonates with hypoxemic respiratory failure, and one
study on patients with sepsis. The administered dose and
duration of iNO varied largely among these studies. In the
ARDS trials, the dose of iNO shifted from a titrated dose
of 1 to 40 ppm in the 1990s to a fixed dose of 5 ppm in
the latest trial [12,23]. The treatment duration was longer
in the ARDS studies (>7 days) than in the non-ARDS
studies (≤7 days).
Reporting of renal dysfunction
Renal dysfunction in these trials was usually defined as
an excess of creatinine level to a predefined level or the
need for renal replacement therapy (Table 1). Among
these trials, three reported the data of two different defi-
nitions of renal dysfunction. Notably, many clinical trials
of iNO were excluded from this systematic review due
to a lack of data on renal adverse effects, especially in
the pediatric studies. Bleeding and neurological complica-
tions were the main concerns for the pediatric patients,
and data on renal dysfunction were rarely reported in the
safety outcomes.Quantitative data synthesis
For the primary outcome of AKI with any severity
(Figure 2), the pooled effect from 10 studies showed that
iNO therapy significantly increased the risk of AKI with
an RR of 1.40 (95% CI, 1.06 to 1.83, P = 0.02, I2 = 0%). The
study by Payen [21] accounted for 39% of meta-analysis
weight but was only published with an abstract. After
omitting this influential study, the effect estimate re-
mained similar (RR, 1.42, 95% CI, 1.003 to 2.01, P = 0.048,
I2 = 0%). The statistical heterogeneity was low among the
analyses.
For the endpoint of AKI requiring renal replacement
therapy (Figure 3), iNO also increased the risk with a RR
of 1.51 (95% CI, 1.09 to 2.11, P = 0.01, I2 = 0%). The effect
estimate became larger after we omitted the influential
study by Payen (RR, 1.76, 95% CI, 1.05 to 2.93, P = 0.03,
I2 = 0%).
Due to the presence of sparse data and imbalance of
trial size, sensitivity analysis was performed to evaluate
the influence of data synthesis methods on the estimate
of summary effect. The effect estimate by the Peto method
was similar to that obtained by the primary analysis with a
random-effects model (Table 2).
Figure 4 shows a funnel plot based on the primary
outcome. The asymmetry of the funnel plot on visual
Table 1 Details of the included randomized controlled trials
Study (year) Country Study population Protocol of iNO therapy Mean iNO
dosage





Dellinger (1998) [12] USA ARDS 1.25, 5.0, 20.0, 40.0, or 80.0 ppm iNO for
28 days or till FiO2 < 0.5
21 ppm 48 Creatinine >2 mg/dL 20/120 7/57
Creatinine ≥3.5 mg/dL 13/120 5/57
Lundin (1999) [20] 11 European
countries
ARDS 1 to 40 ppm iNO at the lowest effective
dose for up to 30 days or until an end point
was reached
9 ppm 57 Creatinine >3.4 mg/dL or
RRT
28/80 12/74
Incident RRT 23/84 10/79
Kinsella (1999) [22] USA Neonate hypoxemic
respiratory failure
5 ppm for 7 days 5 ppm 27 weeks Renal failure 2/48 2/32
Payen (1999) [21] Europe ARDS 10 ppm till PF >250, median 5 days 10 ppm Not
reported
RRT 33/98 26/105
Taylor (2004) [23] USA ARDS 5 ppm until 28 days, discontinuation
of assisted breathing, or death
5 ppm 50 Creatinine ≥3 mg/dL 12/192 8/193
Creatinine ≥3.5 mg/dL 10/192 6/193
Perrin (2006) [24] France Lung
transplantation
20 ppm for 12 h 20 ppm 35 RRT 1/15 1/15
Potapov (2011) [26] USA and Germany Cardiac surgery 40 ppm for 48 h 40 ppm 56 RRT 10/73 8/77
Fernandes (2011)
[25]
Brazil Cardiac surgery 10 ppm for 48 h 10 ppm 46 Urine output <0.3 ml/kg/h 0/14 1/15
Lang (2014) [28] USA Liver transplantation 80 ppm during the operative phase 80 ppm 56 Renal dysfunction 3/40 7/40
Trzeciak (2014) [27] USA Sepsis 40 ppm for 6 h 40 ppm 59 RRT 2/26 1/23









NOTE: Weights are from random effects analysis
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Figure 2 Forest plot for the risk of acute kidney injury. iNO, inhaled nitric oxide.
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creased the risk of AKI. This suggests that the pooled
effect from the current data may underestimate the
effect size of the risk. However, the statistical test for
publication bias, Egger’s test (P = 0.33), did not reach
statistical significance.
The risk of AKI associated with iNO therapy varied
among the different populations (Table 3). The risk was
significantly increased in the patients with ARDS (RR,NOTE: Weights are from random effects analysis

























iNO reduces kidney injury
.005
Figure 3 Forest plot for the risk of initiating renal replacement therap1.55, 95% CI, 1.15 to 2.09, P = 0.005), but not in patients
without ARDS (RR, 0.9, 95%CI, 0.49 to 1.67, P = 0.75).
Among the patients with ARDS, the risk difference for
AKI between iNO and control groups was 0.067 (95%
CI, 0.000 to 0.135, P = 0.05, I2 = 50%), and the number
needed-to-harm to cause one additional AKI was 15.
To test the dose-response relationship between iNO
and the risk of AKI, we performed stratified analysis by
















iNO increases kidney injury 
y. iNO, inhaled nitric oxide.
Table 2 Sensitivity analysis by different data synthesis methods
Outcome measures Number of studies
(number of patients)
Statistical model Effect size (95% CI) P-value (test for effect) Heterogeneity
Acute kidney injury 10 (1337) RR, random-effects 1.40 (1.06 to 1.83) 0.02 I2 = 0%
OR, random-effects 1.50 (1.07 to 2.09) 0.02 I2 = 0%
OR, Peto 1.48 (1.07 to 2.05) 0.02 I2 = 0%
Initiation of renal replacement therapy 5 (595) RR, random-effects 1.51 (1.09 to 2.11) 0.01 I2 = 0%
OR, random-effects 1.73 (1.13 to 2.65) 0.01 I2 = 0%
OR, Peto 1.73 (1.14 to 2.41) 0.01 I2 = 0%
RR, risk ratio; OR, odds ratio.
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(RR, 1.55, 95% CI, 1.15 to 2.09, P = 0.005, four studies),
whereas short-term use did not (RR, 0.90, 95% CI, 0.49
to 1.67, P = 0.75, six studies). Notably, the four studies
involving the prolonged use of iNO are all ARDS stud-
ies. Table 4 summarizes the risk of renal dysfunction for
different iNO exposure levels. We classified the included
studies into three groups according to the cumulative
dose in the stratified analysis. High cumulative dose of
iNO significantly increased the risk of renal dysfunction
but medium and low cumulative doses did not (Table 4).
Figure 5 depicts the relationship between the risk of
renal dysfunction and cumulative dose of iNO. Visual
inspection suggested a possible association between the
cumulative dose and risk of renal dysfunction but statis-
tical test by meta-regression analysis was not significant
due to small sample size (P = 0.10).
Discussion
This meta-analysis updated the evidence on the renal
safety of iNO therapy in ARDS and non-ARDS popula-
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Figure 4 Funnel plot based on the primary outcome.renal dysfunction differed between ARDS and non-ARDS
populations. The results showed that iNO therapy was
associated with a 40% increased risk of renal dysfunction
and the observed effect was mainly attributed to ARDS
studies with prolonged use of iNO. If treating ARDS pa-
tients with iNO the number needed-to-harm to cause one
additional AKI was 15. Sensitivity analysis by different
data pooling methods revealed consistent effect estimates,
and publication bias analysis suggested that the risk may
be underestimated. Clinicians should be aware of this side
effect when using iNO to treat patients. Our review also
found that the safety outcome of renal dysfunction was
not universally reported across iNO trials, especially in
non-ARDS studies. We suggest that future trials of iNO
should report renal safety outcomes.
The risk of renal dysfunction associated with iNO
therapy was first reported in an RCT of patients with
ARDS, in which iNO was found to double the risk of the
need for renal replacement therapy compared with con-
trols [20]. However, this adverse effect did not raise much
attention because subsequent trials of iNO reported no
significant increase in the risk of renal dysfunction [12,23].10
isk ratio)
do 95% confidence limits
Table 3 Subgroup analysis by study population
Subgroups Number of studies
(number of patients)
Risk ratio of AKI (95% CI) P-value (test for effect) Heterogeneity
ARDS 4 (919) 1.55 (1.15 to 2.09) 0.005 I2 = 0%
Non-ARDS 6 (418) 0.90 (0.49 to 1.67) 0.75 I2 = 0%
Surgery 4 (289) 0.89 (0.45 to 1.75) 0.73 I2 = 0%
Sepsis 1 (49) 1.77 (0.17 to 18.26) 0.63 Not applicable
Pediatric hypoxemic respiratory failure 1 (80) 0.67 (0.10 to 4.49) 0.68 Not applicable
AKI, acute kidney injury; ARDS, acute respiratory distress syndrome.
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associated with renal dysfunction in a meta-analysis [13].
This meta-analysis only included ARDS trials because the
primary study interest was the efficacy of iNO on ARDS
[13]. The strengths of our study are the comprehensive
evaluations of iNO-related renal dysfunction among pa-
tients with and without ARDS, the influence of different
endpoints of renal dysfunction, and the dose-response
relationship. Although our analysis suggests that iNO may
increase the risk of renal dysfunction, it is not clear
whether the increased risk is ARDS-specific or related to
prolonged use of iNO. We were unable to clarify this in
study-level analysis because the ARDS studies all involved
the prolonged use of iNO.
Generating awareness of the nephrotoxicity of iNO
has important implications for preventing AKI in the in-
tensive care unit. Previous studies have shown that the
development of AKI significantly increased mortality in
patients with ARDS [29]. We suggest that intensivists
should be cautious about the concurrent use of iNO
with other nephrotoxic agents such as certain antibi-
otics, when treating ARDS. Renal function should be
regularly monitored during iNO therapy to detect pos-
sible AKI early. In addition, the nephrotoxicity of iNO
may partly explain why iNO therapy improves oxygen-
ation and attenuates inflammation but confers no benefit
on mortality in patients with ARDS [3,30,31]. The bene-
fits of iNO may be counterbalanced by the increased risk
of renal failure, because organ failure is positively associ-
ated with mortality [32].
The mechanism of iNO-related renal dysfunction
remains unclear. Table 5 summarizes the findings of
animal and physiological studies on this issue [9,33-38].Table 4 Dose-response relationship between inhaled nitric ox
Cumulative dose of inhaled nitric oxide Numer of studies
(number of patients)
Risk ra
Low 2 (109) 0.56 (0.
Medium 3 (159) 0.64 (0.
High 5 (1069) 1.52 (1.
AKI, acute kidney injury.These studies all examined the effect of short-term expos-
ure to iNO, and most reported that iNO had beneficial ef-
fects on renal function except for a swine study which
reported that iNO promoted renal tubular apoptosis [33].
In this swine model, renal resorption capacity was signifi-
cantly blunted by iNO, and this may have led to tubular
and glomerular injury by means of tubuloglomerular feed-
back [33]. With respect to nitric oxide metabolites, nitric
oxide inhalation increased serum levels of plasma cyclic
guanosine monophosphate (cGMP), nitrate, and nitrite
[39]. These nitric oxide metabolites may play a role in
AKI development owing to the effects on protein nitrosa-
tion and raising oxidative load [40-42]. In an animal
model of drug-induced nephrotoxicity, elevated nitrite
and nitrate levels were observed with increasing oxidative
activity [40]. The induced nephrotoxicity could be amelio-
rated by selective phosphodiesterase-5 inhibitor by sup-
pressing oxidative activity and nitrite and nitrate levels
[40]. In addition, from the pathways of chemical reactions
of nitric oxide in the lung, we speculate that oxidative in-
jury caused by highly oxidant nitrogen compounds may
also play a role in iNO-related kidney injury. Reactive ni-
trogen species such as nitrogen dioxide (NO2) are highly
oxidative compounds that are produced when iNO mixes
with high concentrations of oxygen in the alveoli [3,11].
In patients with ARDS treated with iNO, the serum
concentrations of NO2 have been positively associated
with the dose of iNO administered [12]. It has also been
shown that systemically circulating NO2 may lead to
cytotoxic effects on renal parenchymal cells [43]. This
hypothesis of oxidative injury by reactive nitrogen spe-
cies may also explain why nephrotoxicity tends to de-
velop in patients with ARDS receiving iNO therapy, aside and the risk of acute kidney injury
tio of AKI (95% CI) P-value
(test for effect)
Heterogeneity References
11 to 2.86) 0.49 I2 = 0% [22,25]
23 to 1.81) 0.40 I2 = 0% [24,27,28]
















Cumulative dose of iNO
Figure 5 Bubble plot with fitted meta-regression line depicting
the relationship between the risk of renal dysfunction and
cumulative dose of inhaled nitric oxide (Ino).
Ruan et al. Critical Care  (2015) 19:137 Page 8 of 10these patients usually receive high-concentration oxy-
gen therapy, which may facilitate the production of
reactive nitrogen species. Animal studies are needed to
test this hypothesis.
Limitations
Our study has limitations. First, the included number of
studies and the number of cases in individual studies are
small for the non-ARDS trials. This may have limited
the statistical power of our subgroup analysis and
meta-regression. Second, although the level of statis-
tical heterogeneity was very low in all of our analyses,
the heterogeneity on exposure (treatment duration and
dosage of iNO) should not be overlooked. Third, death
was a competing risk factor in our analysis. However, weTable 5 Animal and human studies investigating the effects o
Study (year) Species Protocols of iNO Ma
Valvini (1995) [38] Human 40 ppm for 3 days followed by
90 ppm for 2 days
1.
2.
Troncy (1997) [9] Swine 40 ppm iNO Inh
rat
Preiser (1998) [37] Human 1 to 20 ppm 1.
2.
Wraight (2001) [36] Human 40 ppm for 2 h Inh
Kielbasa (2001) [35] Rat 49 or 107 ppm iNO for 4 h Hig
an
Da (2007) [34] Swine 30 ppm iNO for 3.5 h De
Gozdzik (2009) [33] Swine 40 ppm iNO for 30 h 1.
2.
Göranson (2014) [44] Swine 30 ppm iNO for 30 h Co
pawere unable to adjust for this competing risk in study-
level analysis. Individual data are needed to conduct such
analyses.
Conclusion
This meta-analysis updated the evidence on the renal
safety of iNO therapy in ARDS and non-ARDS popula-
tions. Our results suggest that iNO therapy substantially
increases the risk of renal dysfunction. It remains unclear
whether this markedly increased risk is disease-specific in
ARDS or related to prolonged use of iNO. Further studies
are needed to clarify this issue. We suggest that renal func-
tion should be monitored during iNO therapy and that
future clinical trials of iNO should evaluate renal safety.
Key messages
 Previous studies have shown that iNO has a good
safety profile and favorable effects on renal and
splanchnic perfusion; however, iNO therapy has been
reported to be associated with renal dysfunction.
 This meta-analysis updated the evidence regarding
renal safety of iNO therapy. The study suggested
that the risk of iNO-associated renal dysfunction
differed between ARDS and non-ARDS populations.
Nitric oxide inhalation may increase the risk of renal
dysfunction, especially with prolonged use and in
patients with ARDS.
 The safety outcome of renal dysfunction was not
universally reported across iNO trials, especially in
non-ARDS studies. We suggest monitoring renal
function during iNO therapy, and that future trials
of iNO should evaluate renal safety.f inhaled nitric oxide (iNO) on the kidneys
in findings
Inhaling 40 ppm nitric oxide would result in a daily nitrogen oxide
load of about 25 mmol.
Impairment of renal function would cause an increase in serum
nitrogen oxides.
aled nitric oxide increased renal blood flow, glomerular filtration
e and urinary flow.
Renal excretion of NO2
− and NO3
− was unaltered by nitric oxide inhalation.
Long-term nitric oxide inhalation was associated with a consistent
increase in the NO3
− plasma concentration.
aled nitric oxide may alter tubular salt and water resorbtion.
h dose of iNO increased nitric oxide synthase III protein expression,
d nitrotyrosine and phosphotyrosine immunoreactivity.
creased swelling and necrosis of glomeruli.
Transient natriuretic effect.
Renal tubular apoptosis promotion after 30 h of iNO treatment.
mbined therapy with iNO and intravenous steroid is associated with
rtial protection of kidney function.
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